The use of the electronic nose in the diagnosis of patients with rheumatoid arthritis or psoriatic arthritis

The use of the electronic nose in the diagnosis of patients with rheumatoid arthritis or psoriatic arthritis - e-nose RA and psoriatic arhtritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36459

Enrollment

Registered

2010-09-17

Start date

2010-07-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis rheumatiod arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: RA patients 18-75 years with: RA according to the ACR criteria DAS28 * 3.2 No medication, or methotrexaat / hydroxychloroquine / sulfasalazine / leflunomide and/or prednison stable use * 28 days;Psoriatic arthritis patients 18-75 years with: PsA according to the CASPAR criteria DAS28 * 3.2 No medication, or methotrexaat / sulfasalazine / leflunomide/ prednison stable use * 28 days;Controls Non-smoking ( 12 months) Rheumatoid factor IgM and anti-CCP negative.

Exclusion criteria

Exclusion criteria: RA and PsA patients Severe cardiovascular disease, history or present (Myocardial infarction, Coronary bypass surgery CVA, Pulmonary embolism and deep venous thrombosis, Heart failure) A history of diabetes mellitus Systemic inflammatory disease other than RA or PsA Active pulmonary disease, including extraarticular manifestation of RA, asthma, COPD, TBC, infection Cancer diagnosed and treated within 5 years, or known incomplete remission if earlier Presence or recent history (4 weeks) of paradontitis History of upper or lower respiratory infection in the past 4 weeks The use of inhalation medication in the past 4 weeks The patient has an active infection or used antibiotics in the last 7 days The patient has started * 28 days for inclusion with oral or systemic corticosteroids in a dosage of > 10 mg a day or has had intramuscular and intraarticular corticosteroids The patient has stopped treatment with etanercept 12 months Eating (including chewing gum), drinking, brushing teeth 10 mg a day or has had intramuscular and intraarticular corticosteroids Eating (including chewing gum), drinking, brushing teeth

Design outcomes

Primary

Measure	Time frame
The primary outcome parameter is the smell-print provided by the electronic nose, together with the results of the on-board and offline statistical analysis.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results